Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baldwin’s Win Bolsters Supplement Caucus In Senate

This article was originally published in The Tan Sheet

Executive Summary

Tammy Baldwin has been a supplement industry caucus member in the House and stakeholders plan to work with her in the Senate. Trade groups closely track the lame duck session of Congress for proposals that would threaten the supplement industry added to legislation to avoid the federal spending “fiscal cliff.”

You may also be interested in...



FDA Works To Clarify Supplement/Food Distinction In Durbin Response

Assistant Commissioner Ireland says FDA is preparing a final guidance on distinguishing liquid supplements from conventional beverages, and a guidance on differences between supplements and foods in general could follow. She cites the challenges of distinguishing the categories in a letter responding to Senator Durbin’s questions about regulation of energy drinks.

People In Brief

Herbalife brings on Dentali as botanical sciences VP; NACDS expands Nicholson’s role; Innophos announces interim CFO; George Hamilton new face of Infusion Life Sciences; Aker BioMarine names sales VP; Atteryd to chair Food Supplements Europe.

FDA Details “Quality Agreements” For Marketers, Contract Manufacturers

The “Contract Manufacturing Arrangements for Drugs: Quality Agreements” draft guidance describes how parties involved in contract manufacturing of drugs can employ quality agreements to delineate their responsibilities and ensure drug quality, safety and efficacy.

Topics

UsernamePublicRestriction

Register

PS106089

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel